Computational methods for optimized biologics formulation
Computational methods for optimized biologics formulation
批准号:
10257518
负责人:
Sunhwan Jo
金额:
$88.58万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-03-05 至 2023-07-31
关键词:
3-DimensionalAddressAdoptionAffinityAreaArginineBaltimoreBehaviorBindingBinding ProteinsBinding SitesBiologicalBiological ProductsBiological Response Modifier TherapyBuffersChemicalsClinicalCodeCollaborationsComputer softwareComputing MethodologiesDataDevelopmentEngineeringExcipientsFDA approvedFailureFormulationGoalsGovernmentGrowthHumanIndustrializationIndustryInsulinLeadLettersLigandsLocationLysineMachine LearningMapsMarylandMembrane ProteinsMethodologyMethodsModelingMolecularMolecular ConformationMonoclonal AntibodiesOutcomePatientsPatternPeptidesPharmaceutical PreparationsPharmacologic SubstancePhaseProbabilityPropertyProtein EngineeringProtein RegionProteinsRecombinantsResearch ContractsRiskRoleSafetySalesSiteStructureSurfaceTechnologyTherapeuticTimeTrainingUniversitiesValidationViscosityWorkbasecommercializationcomputational platformcostdesignexperimental studyflexibilityfunctional groupgraphical user interfaceimprovedinjection/infusioninsightnovel therapeuticsphase 1 studypreventprotein foldingprotein protein interactionprotein structurescreeningsuccesstherapeutic developmentthree dimensional structuretooltrendusability
中文摘要
项目摘要:
基于蛋白质的生物制剂-其活性成分是蛋白质且最常见的是单克隆抗体的治疗剂
抗体(mAb)-构成2000亿美元/年的市场,预计到2025年规模将翻一番。一个关键
生物制剂安全性和有效性的一个重要组成部分是需要在长期使用过程中维持活性蛋白。
储存和随后的注射/输注。为此目的选择赋形剂和缓冲液称为
“formulation.”蛋白质药物的适当配方对于稳定活性蛋白质使其不去折叠至关重要
并封闭折叠蛋白上可能造成聚集风险并导致粘度升高的位点,
不希望的蛋白质-蛋白质相互作用(PPI)。重要的是,可以在不改变序列的情况下进行配制。
因此,它是将生物治疗剂推向市场的独立工具。
目前选择最佳配方的方法是低通量实验,
计算方法不考虑赋形剂-蛋白质相互作用的分子细节。的
建立了配体竞争饱和位点识别(SILCS)计算平台技术
绘制了蛋白质完整3D表面对多种化学官能团的亲和力模式。
然后使用官能团亲和模式来确定可以结合并稳定活性物质的赋形剂,
蛋白质的折叠构象,并与可能参与PPI的蛋白质区域结合,从而抑制
聚集和降低粘度。该提案的总体目标是继续发展和
SILCS生物制剂作为行业就绪工作流程和图形用户界面的验证,
SILCS辅料筛选和PPI分析产生的广泛信息。在拟议的研究中,
将进行实验性的努力,以生成用于各种模型训练和验证的数据,
蛋白质和常用的赋形剂。然后,该数据将与计算的SILCS指标相结合,包括
赋形剂结合位置和亲和力以及可以参与PPI的潜在区域
蛋白质表面,包括pH值的影响和精氨酸作为赋形剂的独特性质。这些信息
然后将在机器学习的背景下应用,以开发预测将阻塞的赋形剂的模型
PPI从而降低粘度和减缓聚集以及稳定折叠的生物活性状态
蛋白质。所提出的模型将在马里兰州,巴尔的摩大学和工业
和政府合作伙伴反对对一系列蛋白质的既定实验方法,
治疗适应症。在项目成功完成后,新的产品将添加到现有的
SILCS软件套件,将最大限度地减少生物制剂的时间和成本要求
从而导致改进的制剂,从而改善临床结果。这些功能将在
直接销售给制药公司和用于合同的行业就绪工作流程的背景
研究生物制剂的优化配方。
英文摘要
Project Summary:
Protein-based biologics – therapeutics whose active ingredient is a protein and most commonly a monoclonal
antibody (mAb) – make up a $200 billion/year market that is expected to double in size by 2025. A critical
component in the safety and efficacy of biologics is the need to maintain the active protein during long-term
storage and subsequent injection/infusion. The selection of excipients and buffers toward this end is termed
“formulation.” Proper formulation of a protein-based drug is essential to stabilize the active protein from unfolding
and to block sites on the folded protein that may pose an aggregation risk and lead to elevated viscosity due to
undesirable protein-protein interactions (PPI). Importantly, formulation can be done without altering the sequence
of (i.e. re-engineering) the protein and is thus an independent tool for bringing a biologic therapeutic to market.
Current approaches to choosing an optimized formulation are either low-throughput experiments or
computational methods that do not take into account the molecular details of excipient-protein interactions. The
established Site Identification by Ligand Competitive Saturation (SILCS) computational platform technology
maps the affinity pattern of the complete 3D surface of a protein for a wide diversity of chemical functional groups.
The functional group affinity pattern is then used to determine excipients that can bind to and stabilize the active,
folded conformation of a protein and bind to regions of the protein that may participate in PPI, thereby inhibiting
aggregation and decreasing viscosity. The broad goal of the proposal is the continued development and
validation of SILCS-Biologics as an industry-ready workflow and a graphical user interface to manage and apply
the extensive information generated by SILCS excipient screening and PPI analysis. In the proposed studies
experimental efforts will be undertaken to generate data for model training and validation across a variety of
proteins and commonly used excipients. That data will be then combined with computed SILCS metrics including
excipient binding locations and affinities and potential regions that can participate in PPI across the complete
protein surface, including the impact of pH and the unique properties of Arginine as an excipient. This information
will then be applied in the context of machine learning to develop models that will predict excipients that will block
PPI thereby lowering viscosity and slowing aggregation as well as stabilize the folded, biologically active state
of the protein. The proposed models will be validated at the University of Maryland, Baltimore and with industrial
and government partners against established experimental methods on a range of proteins with various
therapeutic indications. Upon successful completion of the project new offerings will be added to the existing
SILCS software suite that will minimize the time and costs requirements for the formulation of biologics as well
as lead to improved formulations thereby improving clinical outcomes. These capabilities will be implemented in
the context of industry-ready workflows for direct sale to pharmaceutical companies and for use in contract
research for the optimized formulation of biologics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金